

Luigi F Meneghini

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9354720/luigi-f-meneghini-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

1,873
citations

25
h-index

41
g-index

106
ext. papers

2,128
ext. citations

4.8
avg, IF

4.86
L-index

#	Paper	IF	Citations
94	Lower-Extremity Amputation Trends Among People With Diabetes in a Large Urban Environment. <i>Diabetes Care</i> , 2021 , 44, e91-e92	14.6	1
93	Target attainment in insulin-naïve patients at high risk for hypoglycemia: Results from ACHIEVE Control. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107831	3.2	
92	Decolonizing Care at Diagnosis: Culture, History, and Family at an Urban Inter-tribal Clinic. <i>Medical Anthropology Quarterly</i> , 2021 , 35, 364-385	2.5	0
91	Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2137-2154	6.7	10
90	Daniel H. Mintz (1930-2020): An Extraordinary Physician-Scientist and a Pioneer in Islet Transplantation. <i>Diabetes Care</i> , 2021 , 44, 1727-1733	14.6	
89	Type 2 Diabetes and HbA1c Predict All-Cause Post-Metabolic and Bariatric Surgery Hospital Readmission. <i>Obesity</i> , 2021 , 29, 71-78	8	2
88	Optimizing Glucose Meter Downloads at Parkland Diabetes Clinic. <i>Clinical Diabetes</i> , 2021 , 39, 199-202	2.9	
87	Multilevel Variation in Diabetes Screening Within an Integrated Health System. <i>Diabetes Care</i> , 2020 , 43, 1016-1024	14.6	2
86	Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1995-2003	6.7	5
85	Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. <i>Diabetic Medicine</i> , 2020 , 37, 267-276	3.5	5
84	Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. <i>Clinical Diabetes</i> , 2020 , 38, 371-381	2.9	20
83	A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2004-2012	6.7	6
82	Physician survey on pre-/postprocedure measures for injectable treatments. <i>Journal of Cosmetic Dermatology</i> , 2020 , 19, 2246-2251	2.5	
81	Design and Implementation of an Electronic Tool to Measure Medication Adherence at the Point of Care. <i>Clinical Diabetes</i> , 2020 , 38, 382-385	2.9	
80	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. <i>Diabetes Care</i> , 2020 , 43, 2847-2852	14.6	3
79	A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2133-2141	6.7	2
78	Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. <i>Diabetes Therapy</i> , 2019 , 10, 617-633	3.6	35

77	The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1429-1436	6.7	21
76	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. <i>Advances in Therapy</i> , 2019 , 36, 2310-2326	4.1	
75	Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2019 , 2, e00073	2.7	5
74	Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2019 , 32, 303-311	1.9	2
73	Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. <i>Current Medical Research and Opinion</i> , 2019 , 35, 525-533	2.5	2
72	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 321-329	6.7	10
71	Diabetic Skin Changes Can Benefit from Moisturizer and Cleanser Use: A Review. <i>Journal of Drugs in Dermatology</i> , 2019 , 18, 1211-1217	2.2	3
70	Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1298-1301	6.7	4
69	Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1156-1165	6.7	9
68	Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. <i>Diabetes Therapy</i> , 2018 , 9, 1347-1358	3.6	36
67	Change in Insulin Dose and HbA1c by Geographical Region: Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study. <i>Diabetes</i> , 2018 , 67, 1037-P	0.9	1
66	Implementation of a Perioperative Insulin Protocol in an Advanced Practice Provider (APP)-Led Limb Salvage Hospitalist Team. <i>Diabetes</i> , 2018 , 67, 2315-PUB	0.9	
65	Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Targets: Analyses from the DUAL Program. <i>Diabetes</i> , 2018 , 67, 1109-P	0.9	
64	Does Improving Glycemic Control Accelerate Healing of Diabetic Foot Ulcers?. <i>Diabetes</i> , 2018 , 67, 2218-PUB	0.9	1
63	Diabetes Foot Wound Healing: A Collaborative Approach. <i>Diabetes</i> , 2018 , 67, 645-P	0.9	
62	Diabetes Inside: Following the Long-Term Impact of a Diabetes Quality Improvement (QI) Initiative in Primary Care. <i>Diabetes</i> , 2018 , 67, 7-OR	0.9	
61	Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 831-839	6.7	11
60	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. <i>Diabetes Therapy</i> , 2018 , 9, 2043-2053	3.6	6

59	More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2314-2318	6.7	13
58	Role of Devices in Insulin Delivery. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 76-78	8.1	4
57	Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1155-1164	6.7	76
56	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 315-322	8.1	3
55	Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. <i>Postgraduate Medicine</i> , 2016 , 128, 731-739	3.7	14
54	New insulin preparations: A primer for the clinician. <i>Cleveland Clinic Journal of Medicine</i> , 2016 , 83, S27-33	3.8	9
53	Clinical use of insulin degludec. <i>Diabetes Research and Clinical Practice</i> , 2015 , 109, 19-31	7.4	43
52	Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. <i>Diabetes/Metabolism Research and Reviews</i> , 2015 , 31, 537-44	7.5	11
51	Stepwise addition of prandial insulin. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 3-4	18.1	1
50	Insulin stacking versus therapeutic accumulation: understanding the differences. <i>Endocrine Practice</i> , 2014 , 20, 75-83	3.2	47
49	Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. <i>Journal of Diabetes</i> , 2014 , 6, 243-50	3.8	6
48	Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. <i>Patient</i> , 2014 , 7, 437-50	3.7	43
47	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. <i>European Endocrinology</i> , 2014 , 10, 23-30	3.4	11
46	Insulin therapy for type 2 diabetes. <i>Endocrine</i> , 2013 , 43, 529-34	4	8
45	The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 858-64	14.6	186
44	Intensifying insulin therapy: what options are available to patients with type 2 diabetes?. <i>American Journal of Medicine</i> , 2013 , 126, S28-37	2.4	24
43	Screening, evaluation and management of depression in people with diabetes in primary care. <i>Primary Care Diabetes</i> , 2013 , 7, 1-10	2.4	73
42	Insulin degludec improves health-related quality of life (SF-36) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. <i>Diabetic Medicine</i> , 2013 , 30, 226-32	3.5	29

41	Bariatric intervention effective at reversing Type 2 diabetes. <i>Evidence-Based Medicine</i> , 2013 , 18, 68-9		
40	Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. <i>Endocrine Practice</i> , 2013 , 19, 718-28	3.2	7
39	Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013 , 15, 729-36	6.7	39
38	Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. <i>Endocrine Practice</i> , 2013 , 19, 462-70	3.2	16
37	Study of Once Daily Levemir (SOLVE) insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2012 , 14, 654-61	6.7	83
36	Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. <i>Diabetic Medicine</i> , 2012 , 29, 716-20	3.5	27
35	Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2012 , 7, 9-14	4.1	10
34	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2012 , 28, 258-67	7.5	14
33	Individualizing insulin therapy. <i>Journal of Family Practice</i> , 2012 , 61, S13-27	0.2	1
32	Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes. <i>Clinical Immunology</i> , 2011 , 139, 290-301	9	22
31	Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. <i>Endocrine Practice</i> , 2011 , 17, 727-36	3.2	54
30	Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011 , 34, 661-5	14.6	140
29	Insulin for intensifying diabetes treatment. <i>Journal of Family Practice</i> , 2011 , 60, S21-8	0.2	
28	Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections. <i>Diabetes Technology and Therapeutics</i> , 2010 , 12 Suppl 1, S109-14	8.1	7
27	Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. <i>American Journal of Nephrology</i> , 2010 , 31, 110-6	4.6	14
26	Letter to the editor Insulin - Volume 5, Issue 1. <i>Insulin</i> , 2010 , 5, 63-65		
25	"Will I have to be on insulin for the rest of my life?": Introduction. <i>Primary Care Diabetes</i> , 2010 , 4 Suppl 1, S1-2	2.4	1
24	Insulin detemir: A historical perspective on a modern basal insulin analogue. <i>Primary Care Diabetes</i> , 2010 , 4 Suppl 1, S31-42	2.4	18

23	Practical guidance to insulin management. <i>Primary Care Diabetes</i> , 2010 , 4 Suppl 1, S43-56	2.4	12
22	Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. <i>Endocrine Practice</i> , 2010 , 16, 588-99	3.2	29
21	Early insulin treatment in type 2 diabetes: what are the pros?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S266-9	14.6	31
20	Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. <i>Advances in Therapy</i> , 2009 , 26, 194-207	4.1	7
19	Perioperative management of diabetes: translating evidence into practice. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 4, S53-9	2.8	36
18	Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 11-20	2.5	35
17	Clarification of the similarities and differences among insulin analog preparations: response to Becker. <i>Diabetes Technology and Therapeutics</i> , 2008 , 10, 51-3; author reply 54-6	8.1	1
16	Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 513-529		1
15	Superior mesenteric artery syndrome in type 1 diabetes masquerading as gastroparesis. <i>Diabetes Care</i> , 2008 , 31, 1983-4	14.6	11
14	Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. <i>International Journal of Clinical Practice</i> , 2008 , 62, 659-65	2.9	56
13	Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. <i>International Journal of Clinical Practice</i> , 2008 , 62, 1255-64	2.9	9
12	Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 11-20	2.5	10
11	The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. <i>Diabetes, Obesity and Metabolism</i> , 2007 , 9, 902-13	6.7	100
10	Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial. <i>Diabetes Technology and Therapeutics</i> , 2007 , 9, 254-64	8.1	15
9	Why and how to use insulin therapy earlier in the management of type 2 diabetes. <i>Southern Medical Journal</i> , 2007 , 100, 164-74	0.6	15
8	Appropriate advancement of type 2 diabetes therapy. <i>Journal of Family Practice</i> , 2007 , 56, 19A-29A; quiz 30A	0.2	
7	Prevalence and associations of binge eating disorder in a multiethnic population with type 2 diabetes. <i>Diabetes Care</i> , 2006 , 29, 2760	14.6	47
6	Pharmacotherapies for diabetes management: an update for the practicing clinician. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2006 , 18, 379-89	1.7	3

5	How good is your glucose control?. <i>Diabetes Technology and Therapeutics</i> , 2005 , 7, 863-75	8.1	7
4	Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. <i>Diabetes, Obesity and Metabolism</i> , 2005 , 7, 88-97	6.7	58
3	Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. <i>Cell Transplantation</i> , 2005 , 14, 77-84	4	30
2	Obesity, bariatric surgery and type 2 diabetes--a systematic review. <i>Diabetes/Metabolism Research and Reviews</i> , 2004 , 20, 438-45	7.5	70
1	Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. <i>Clinical Therapeutics</i> , 2004 , 26, 379-89	3.5	33